Sun Pharma Advanced Research Company Limited reported unaudited earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, the company reported income from operation of INR 42.2 million compared to INR 45.1 million a year ago. Loss from operations before other income and finance cost was INR 232.0 million compared to INR 183.8 million a year ago. Loss before finance costs and tax was INR 228.6 million compared to INR 178.4 million a year ago. Loss after finance costs and before tax was INR 240.9 million compared to INR 179.0 million a year ago. Loss after tax for the period or year from ordinary activities was INR 240.9 million compared to INR 179.0 million a year ago. Basic and diluted loss per share was INR 1.07 compared to INR 0.85 a year ago.

For the nine months, the company reported income from operation of INR 154.5 million compared to INR 247.6 million a year ago. Loss from operations before other income and finance cost was INR 650.0 million compared to INR 510.2 million a year ago. Loss before finance costs and tax was INR 644.5 million compared to INR 504.4 million a year ago. Loss after finance costs and before tax was INR 665.3 million compared to INR 506.4 million a year ago. Loss after tax for the period or year from ordinary activities was INR 665.3 million compared to INR 506.4 million a year ago. Basic and diluted loss per share was INR 3.09 compared to INR 2.41 a year ago.